SCM
EBS icon

Snyder Capital Management’s Emergent Biosolutions EBS Stock Holding History

Snyder Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-204,300
Closed -$8.39M – 73
2022
Q1 		$8.39M Sell
204,300
-479,400
-70% -$21.1M 0.21% 75
2021
Q4 		$29.7M Sell
683,700
-160,054
-19% -$7.24M 0.72% 52
2021
Q3 		$42.2M Buy
843,754
+43,331
+5% +$2.62M 1.12% 33
2021
Q2 		$50.4M Buy
800,423
+30,991
+4% +$1.99M 1.41% 24
2021
Q1 		$71.5M Buy
769,432
+45,955
+6% +$4.71M 2.06% 13
2020
Q4 		$64.8M Buy
723,477
+58,815
+9% +$5.4M 2.12% 15
2020
Q3 		$68.7M Sell
664,662
-226,034
-25% -$24.4M 2.94% 10
2020
Q2 		$70.4M Sell
890,696
-141,163
-14% -$10.5M 3.19% 7
2020
Q1 		$59.7M Sell
1,031,859
-121,512
-11% -$7M 3.4% 3
2019
Q4 		$62.2M Sell
1,153,371
-28,992
-2% -$1.57M 2.45% 15
2019
Q3 		$61.8M Buy
1,182,363
+195,635
+20% +$9.11M 2.71% 13
2019
Q2 		$47.7M Sell
986,728
-35,291
-3% -$1.69M 2.14% 17
2019
Q1 		$51.6M Buy
1,022,019
+55,029
+6% +$3.25M 2.44% 14
2018
Q4 		$57.3M Sell
966,990
-146,208
-13% -$9.43M 3.1% 9
2018
Q3 		$73.3M Sell
1,113,198
-19,624
-2% -$1.15M 3.26% 9
2018
Q2 		$57.2M Sell
1,132,822
-91,555
-7% -$4.77M 2.71% 12
2018
Q1 		$64.5M Sell
1,224,377
-18,144
-1% -$904K 3.18% 10
2017
Q4 		$57.7M Buy
1,242,521
+144,332
+13% +$6.08M 2.88% 12
2017
Q3 		$44.4M Buy
1,098,189
+4,870
+0.4% +$176K 2.22% 14
2017
Q2 		$37.1M Sell
1,093,319
-41,013
-4% -$1.27M 1.96% 18
2017
Q1 		$32.9M Buy
1,134,332
+171,636
+18% +$5.22M 1.74% 24
2016
Q4 		$31.6M Buy
962,696
+187,276
+24% +$5.61M 1.92% 21
2016
Q3 		$24.4M Buy
775,420
+242,073
+45% +$7.03M 1.53% 28
2016
Q2 		$15M Buy
533,347
+227,733
+75% +$8.93M 0.98% 37
2016
Q1 		$11.1M Sell
305,614
-24,306
-7% -$859K 0.75% 41
2015
Q4 		$13.2M Buy
+329,920
New +$11.5M 0.91% 37

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Snyder Capital Management's EBS Position: Q2 2022 in Review

Snyder Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 204,300 shares — an estimated $8.39M sold.

Snyder Capital Management first reported a position in EBS in Q4 2015 and held it in 26 quarters. The position peaked at $73.3M in Q3 2018. 231 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Snyder Capital Management reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Snyder Capital Management sold 204,300 Emergent Biosolutions shares in Q2 2022, an estimated $8.39M.
  • Snyder Capital Management first reported a position in Emergent Biosolutions in Q4 2015 and held it in 26 quarters.
  • Snyder Capital Management's Emergent Biosolutions position peaked at $73.3M in Q3 2018.
  • 231 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Snyder Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.